Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection-Reference-Cited by-同舟云学术

Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection

Published:2019-07 Issue:7 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Lv Xiaoju¹,Alder Jeff²,Li Li³,O’Riordan William⁴,Rybak Michael J.⁵,Ye Hui¹,Zhang Ruiping⁶,Zhang Zhongqi⁶,Zhu Xu⁶,Wilcox Mark H.⁷

Affiliation:

1. Centre of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China

2. Bayer HealthCare Pharmaceuticals, Whippany, New Jersey, USA

3. Bayer AG, Berlin, Germany

4. eStudy Site, Inc., San Diego, California, USA

5. Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University School of Medicine, Detroit, Michigan, USA

6. Bayer HealthCare, Beijing, China

7. Leeds Teaching Hospitals and University of Leeds, Leeds, United Kingdom

Abstract

Tedizolid phosphate is approved for the treatment of acute bacterial skin and skin structure infection (ABSSSI) caused by Gram-positive bacteria in the United States, Europe, and other countries. In this multicenter, double-blind, phase 3 study, 598 adult ABSSSI patients in China, Taiwan, the Philippines, and the United States were randomized to receive 200 mg of tedizolid, intravenously (i.v.)/orally (p.o.), once daily for 6 days or 600 mg of linezolid, i.v./p.o.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02252-18

Reference42 articles.

1. World Health Organization. 2017. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. World Health Organization, Geneva, Switzerland.

2. Outcome and Attributable Mortality in Critically Ill Patients With Bacteremia Involving Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus

3. Adverse Clinical and Economic Outcomes Attributable to Methicillin Resistance among Patients withStaphylococcus aureusSurgical Site Infection

4. Epidemiology, microbiology and treatment implications in adult patients hospitalized with pneumonia in different regions of China: a retrospective study

5. Reevaluation of the impact of methicillin-resistance on outcomes in patients with Staphylococcus aureus bacteremia and endocarditis

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of oxazolidinones (linezolid or tedizolid) for the treatment of breast infections. A case series from a tertiary referral hospital;Infection;2024-05-01

2. Recent advances in the exploration of oxazolidinone scaffolds from compound development to antibacterial agents and other bioactivities;European Journal of Medicinal Chemistry;2024-04

3. Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future;Expert Opinion on Drug Safety;2023-12-25

4. Parenteral Vancomycin in the Treatment of MRSA-Associated Diabetic Foot Infections: An Unnecessary Risk;The International Journal of Lower Extremity Wounds;2023-10-27

5. Physicochemical Characteristics of Antimicrobials and Practical Recommendations for Intravenous Administration: A Systematic Review;Antibiotics;2023-08-19